Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Deep dive into rare mouth cancer could unlock personalized treatments

NCT ID NCT07662694

Knowledge-focused Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a rare type of cancer called oral mucosal melanoma. Researchers want to improve how the cancer is staged by measuring how deep it goes into tissue and by studying its genetic makeup. They will follow 1,100 patients over time to see which treatments work best for different tumor types. The goal is to create a more precise system for guiding therapy and predicting outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate staging and personalized treatments for oral mucosal melanoma, potentially improving survival.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not apply to non-Chinese populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Histopathologically confirmed primary oral mucosal melanoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed primary oral mucosal melanoma (WHO criteria); Primary site: oral mucosa (palate, gingiva, sublingual, buccal, hard palate, floor of mouth); Receiving or planning standard treatment (surgery, radiotherapy, chemotherapy, immunotherapy, or targeted therapy); Age ≥18 years, any sex; Complete clinical data with pathology, imaging, and records (retrospective) OR willingness for long-term follow-up (prospective); Signed informed consent (prospective) or data meeting ethical waiver (retrospective). Exclusion Criteria: * Primary melanoma originating from skin, eye, esophagus, or other non-oral mucosal sites; Secondary/metastatic oral mucosal melanoma (primary not in oral cavity); Unavailable key clinical information (surgical records, pathology, imaging); Prior or concurrent other malignancy interfering with prognosis; Severe mental/cognitive disorders or poor compliance; Severe comorbidities (heart failure, liver/renal failure) affecting treatment or survival analysis; Patient refusal or withdrawal of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mucosal melanoma of the head and neck are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mucosal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mucosal melanoma of the head and neck Oral melanoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,

    Shanghai, Shanghai Municipality, 200011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.